MacroGenics Closes Solid Tumor Clinical Trial After 7 People Die
MacroGenics has closed a phase 2 clinical trial of its anti-cancer antibody enoblituzumab after learning of seven deaths potentially associated with hemorrhagic events. The setback means two of MacroGenics’ three attacks on the protein B7-H3 have hit setbacks, but the biotech is forging ahead with the third candidate.
Having stopped development of a B7-H3xCD3 bispecific early in 2020, MacroGenics continued to push a monoclonal antibody, enoblituzumab, and antibody-drug conjugate (ADC), MGC018, against the immune checkpoint deeper into the clinic. The biotech moved the monoclonal into a combination phase 2 clinical trial in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) last year.
Now, the study has come to an abrupt halt. MacroGenics closed the clinical trial after seven of the 62 participants died. The deaths were potentially linked to hemorrhagic events, a known risk for SCCHN but one that occurs at a lower rate than seen in the phase 2 study.
Read the full article at: www.fiercebiotech.com
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
